Interleukin‐12/23 deficiency differentially affects pathology in male and female Alzheimer's disease‐like mice

Pathological aggregation of amyloid‐β (Aβ) is a main hallmark of Alzheimer's disease (AD). Recent genetic association studies have linked innate immune system actions to AD development, and current evidence suggests profound gender differences in AD pathogenesis. Here, we characterise gender‐sp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EMBO reports 2020-03, Vol.21 (3), p.e48530-n/a
Hauptverfasser: Eede, Pascale, Obst, Juliane, Benke, Eileen, Yvon‐Durocher, Genevieve, Richard, Bernhard C, Gimber, Niclas, Schmoranzer, Jan, Böddrich, Annett, Wanker, Erich E, Prokop, Stefan, Heppner, Frank L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Pathological aggregation of amyloid‐β (Aβ) is a main hallmark of Alzheimer's disease (AD). Recent genetic association studies have linked innate immune system actions to AD development, and current evidence suggests profound gender differences in AD pathogenesis. Here, we characterise gender‐specific pathologies in the APP23 AD‐like mouse model and find that female mice show stronger amyloidosis and astrogliosis compared with male mice. We tested the gender‐specific effect of lack of IL12p40, the shared subunit of interleukin (IL)‐12 and IL‐23, that we previously reported to ameliorate pathology in APPPS1 mice. IL12p40 deficiency gender specifically reduces Aβ plaque burden in male APP23 mice, while in female mice, a significant reduction in soluble Aβ 1–40 without changes in Aβ plaque burden is seen. Similarly, plasma and brain cytokine levels are altered differently in female versus male APP23 mice lacking IL12p40, while glial properties are unchanged. These data corroborate the therapeutic potential of targeting IL‐12/IL‐23 signalling in AD, but also highlight the importance of gender considerations when studying the role of the immune system and AD. Synopsis Abrogating IL‐12/IL‐23 signaling ameliorates amyloidogenesis gender‐specifically in APP23 mice, indicating therapeutic potential of targeting IL‐12/IL‐23 in Alzheimer's disease and highlighting the importance of gender considerations in AD. Female APP23 mice show stronger amyloidosis compared with male mice. Lack of IL‐12/IL‐23 signaling reduces Aβ plaque load in male APP23 mice and affects plasma IFNγ levels. In female APP23 mice, deficiency in IL‐12/IL‐23 signaling reduces soluble Aβ1‐40 and modulates various brain and plasma cytokines. Graphical Abstract Abrogating IL‐12/IL‐23 signaling ameliorates amyloidogenesis gender‐specifically in APP23 mice, indicating therapeutic potential of targeting IL‐12/IL‐23 in Alzheimer's disease and highlighting the importance of gender considerations in AD.
ISSN:1469-221X
1469-3178
DOI:10.15252/embr.201948530